Female Hormone Therapy
Research at the Center for Biomedical Research is part of the Council's ongoing efforts to evaluate the long-term safety of the progesterone receptor modulator CDB-2914 for hormone therapy.
Selecting a progestin for female hormone therapy (HT) involves several considerations. In addition to its efficacy, and of paramount importance, a progestin for HT should exhibit the highest benefit-to-risk ratio.
Physiological levels of progestins can promote either proliferation or differentiation in breast tissue. A progestin for HT should either have no growth-promoting effects or exert an antiproliferative effect on breast tissue. Studies of combined estrogen and progestin treatments have indicated an increased risk of breast cancer with long-term use of hormone replacement therapy (HRT). In abnormal breast tissue, certain progestins can decrease or increase tumor growth.
The antiprogestin CDB-2914 is a progesterone receptor modulator (PRM). To determine the potential for safe inclusion of CDB-2914 in contraception and HRT, the biological properties of this PRM on growth and hormone responsiveness of human mammary adenocarcinoma (MCF-7) cells were further studied. Utilizing this breast cancer model system, several biological parameters shown to be useful prognostic indicators for breast cancer progression were monitored. Using flow cytometry, the cell cycle status of synchronized MCF-7 cells following a 24-hour treatment with 17β-estradiol (E2), progesterone, or CDB-2914 was analyzed. In contrast to E2, CDB-2914 had no mitogenic effect upon MCF-7 cells when used alone or in combination with E2. New data from these molecular biology studies suggest that CDB-2914 may offer additional advantages for contraception and hormone replacement.
Central modifications of allopregnanolone and ß-endorphin following subcutaneous administration of Nestorone (abstract)
Lenzi,E.; Pluchino,N.; Begliuomini,S.; Casarosa,E.; Merlini,S.; Giannini,A.; Luisi,M.; Kumar,Narender; Sitruk-Ware,Regine; Genazzani,Andrea R.
Journal of Steroid Biochemistry and Molecular Biology 116(1-2): 15-20
Publication date: 2009
Parenteral administration of progestins for hormonal replacement therapy (abstract)
Nath,Anita; Sitruk-Ware,Regine
European Journal of Contraception and Reproductive Health Care 14(2): 88-96
Publication date: 2009
Pharmacology and clinical applications of selective estrogen receptor modulators (abstract)
Nath,Anita; Sitruk-Ware,Regine
Climacteric 12(3): 188-205
Publication date: 2009
Progesterone and progestins: Neuroprotection and myelin repair (abstract)
Schumacher,Michael; Sitruk-Ware,Regine; De Nicola,Alejandro
Current Opinion in Pharmacology 8(6): 740-746
Publication date: 2008
Effects of estradiol with oral or intravaginal progesterone on risk markers for breast cancer in a postmenopausal monkey model (abstract)
Wood,Charles E.; Sitruk-Ware,Regine; Tsong,Yun-yen; Register,Thomas C.; Lees,Cynthia J.; Cline,J.Mark
Menopause 14(4): 1-9
Publication date: 2007
Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, cross-over study (abstract)
Sitruk-Ware,Regine; Plu-Bureau,Genevieve; Menard,Joel; Conard,Jacqueline; Kumar,Sushma; Thalaband,Jean-Christophe; Tokay,Barbara A.; Bouchard,Philippe
Journal of Clinical Endocrinology and Metabolism 92(6): 2074-2079
Publication date: 2007
Preclinical and clinical properties of trimegestone: A potent and selective progestin (abstract)
Sitruk-Ware,Regine; Bossemeyer,Ronald; Bouchard,Philippe
Gynecological Endocrinology 23(6): 310-319
Publication date: 2007
Routes of delivery for progesterone and progestins (abstract)
Sitruk-Ware,Regine
Maturitas 57(1): 77-80
Publication date: 2007
Cyclical mastalgia and breast cancer risk: Results of a French cohort study (abstract)
Plu-Bureau,Genevieve; Le,Monique G.; Sitruk-Ware,Regine; Thalaband,Jean-Christophe
Cancer Epidemiology Biomarkers & Prevention 15(6): 1229-1231
Publication date: 2006
Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells (abstract)
Xu,Qin; Ohara,Noriyuki; Chen,Wei; Liu,Jin; Sasaki,Hiroko; Morikawa,Akira; Sitruk-Ware,Regine; Johansson,Elof D.B.; Maruo,Takeshi
Human Reproduction 21(9): 2408-2416
Publication date: 2006
Pharmacology of different progestogens: The special case of drospirenone (abstract)
Sitruk-Ware,Regine
Climacteric 8(suppl 3): 4-12
Publication date: 2005
Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells (abstract)
Xu,Qin; Takekida,Shigeki; Ohara,Noriyuki; Chen,Wei; Sitruk-Ware,Regine; Johansson,Elof D.B.; Maruo,Takeshi
Journal of Clinical Endocrinology and Metabolism 90(2): 953-961
Publication date: 2005
New progestogens: A review of their effects in perimenopausal and postmenopausal women (abstract)
Sitruk-Ware,Regine
Drugs and Aging 21(13): 865-883
Publication date: 2004
Pharmacological profile of progestins (abstract)
Sitruk-Ware,Regine
Maturitas 47(4): 277-283
Publication date: 2004
Alternatives for optimal hormone replacement therapy (abstract)
Sitruk-Ware,Regine
Climacteric 6(suppl 2): 11-16
Publication date: 2003
Controversy about hormone therapy: Implications for Population Council research
Presentation at 115th Meeting of the Board of Trustees, Population Council, New York, 14 January
Sitruk-Ware,Regine; Morris,Patricia L.
Publication date: 2003
Effect of CDB-2914 on breast cells
Presentation at 83rd meeting of the International Committee for Contraception Research, Santiago, Chile, November
Sitruk-Ware,Regine
Publication date: 2003
Hormone therapy and the cardiovascular system: The critical role of progestins (abstract)
Sitruk-Ware,Regine
Climacteric 6(suppl 3): 21-28
Publication date: 2003
Project Stats
Location: United States
Program(s):
Reproductive Health
Topic(s):
New and improved reproductive technologies
Technologies for women
Duration: 1/2001 - ongoing
Population Council researchers:
Patricia L. Morris
Régine Sitruk-Ware
Donors:
National Institute of Child Health and Human Development
Get Involved
- Make a contribution to the Population Council
- Honor a loved one with a gift in their name
- Sign up to receive e-mail announcements
Connect
